What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

Original reporting
Published Nov 9, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Compugen (CGEN) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$CGENBullishMed
01

Why it matters

Earnings beat and cash runway may prompt short‑term buying, while pending milestones could drive longer‑term upside.

02

Market read

Q3 earnings provide fresh financial data for CGEN, indicating improved loss profile and strong cash, which may influence short‑term price action.

03

What to watch

Milestone payments from AstraZeneca and Gilead could boost future cash flow beyond the disclosed numbers.

Relevance 7/10Novelty 7/10Timing: post‑earnings Q3 release

Background

Compugen (NASDAQ:CGEN) discussed its partnership milestones with AstraZeneca and Gilead and presented Q3 financial results.

Company-level read

Ticker impact

$CGENBullishHigh confidence
Context

Q3 earnings disclosed revenue $3.8M, net loss $5.8M and cash $117.5M, new financial figures not previously public.

Expected impact

modest upside as market prices in improved loss profile and cash runway

Evidence & confidence

First report of Q3 results shows better-than-expected loss narrowing and cash balance, likely to support short-term buying.

Market effects

Strengthens outlook for AI‑driven biotech discovery platforms.

Limited to US biotech micro‑cap segment.

Low global impact; primarily relevant to investors in CGEN.

Counterpoint

Losses remain sizable; investors may remain cautious despite narrowing.

Key entities

  • Compugen Ltd.

    Israeli clinical‑stage biotech focused on AI‑driven target discovery.

  • AstraZeneca

    Pharma partner with potential $195M milestones.

  • Gilead Sciences

    Pharma partner with $90M payments and up to $758M milestones.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.

$NVDAHighAI 9/10

Nvidia earnings beat lifts Bitcoin mining stocks

Nvidia (NVDA) reported Q3 2026 earnings, beating estimates with $2.68 EPS and $115.8B revenue. Data center revenue rose 110% YoY. Q4 outlook is $127.4B-$132.6B, above analyst estimates. Bitcoin mining stocks like MARA, HUT, RIOT, IREN, and CRWV rose, as some pivot to AI due to rising mining costs and Bitcoin's price drop.